Skip to main content

SJIA clinical trials at UCLA

1 research study open to eligible people

Showing trials for
  • PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

    open to eligible people ages 6 months to 80 years

    The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.

    Los Angeles, California and other locations

Last updated: